CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 15, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 9, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy , M.D., as Chief Scientific Officer. Dr....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019 , in...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- Synlogic (Nasdaq:SYBX) announced today that Caroline Kurtz , Ph.D., Synlogic’s Head of Metabolism, will provide a corporate update at Oppenheimer’s 29th Annual Healthcare Conference at 3:20 pm ET on Wednesday, March 20, 2019 , in New York City ....

– Ended 2018 with approximately $123 million in cash and investments, which provides runway through 2020 – – Clinical trial readouts expected in mid-2019 from two Synthetic Biotic ™ medicines and first IND application expected from Synlogic’s immuno-oncology platform in second half of 2019 – –...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2018 financial results before the...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will present at the following upcoming investor conferences: Chardan’s 1 st Annual Microbiome Medicines Summit at 2:05pm ET...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the SVB Leerink 8th Annual Global Healthcare Conference at 1:30 pm ET on Thursday,...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2019-- Synlogic, Inc. , (Nasdaq:SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Patricia N. Hurter , Ph.D., Senior Vice President of Pharmaceutical...

–Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism– – Data from ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia expected mid-2019 – CAMBRIDGE, Mass....

– Presentation of topline clinical data from studies of Synthetic Biotic™ medicines, SYNB1020 and SYNB1618, in patients expected mid-2019 – – Investigational New Drug (IND) application for SYNB1891, Synlogic’s first immuno-oncology program, expected in 2H2019 – CAMBRIDGE, Mass....